SAL067 clinical trials
Also written SAL067.
How each study uses SAL067 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses SAL067 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal InsufficiencyCompletedPhase 1Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT06883656Written as SAL067
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by MetforminCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT05801627Written as SAL067
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT05782192Written as SAL067